Education
About Us
Working with TipRanks
Follow Us
Crescent Biopharma (CBIO)
NASDAQ:CBIO
CBIO Stock Chart & Stats
$12.09
--
Market closed
$12.09
--
Day’s Range― - ―
52-Week Range$8.72 - $28.77
Previous CloseN/A
VolumeN/A
Average Volume (3M)145.41K
Market Cap
$333.16M
Enterprise Value$121.61M
Total Cash (Recent Filing)$213.19M
Total Debt (Recent Filing)$1.64M
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Apr 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.01
Shares Outstanding27,556,767
10 Day Avg. Volume163,515
30 Day Avg. Volume145,412
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)6.08
Price to Sales (P/S)0.00
P/FCF Ratio-17.05
Enterprise Value/Market Cap0.37
Enterprise Value/Revenue2.94
Enterprise Value/Gross Profit3.06
Enterprise Value/Ebitda-0.87
Forecast
1Y Price Target
$29.71Price Target Upside145.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-5.34
Revenue Forecast (FY)$2.63M
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentThe ASCEND global Phase 1/2 study has dosed the first patient for CR-001, initiating human testing that can generate early safety and tumor response data to inform dose selection and potential registrational plans.
Regulatory ProgressUS FDA clearance of the investigational new drug application for CR-001 removes a key regulatory barrier and permits the company to proceed with formal clinical testing of its PD-1 x VEGF bispecific.
Strategic PartnershipA strategic collaboration grants regional partner rights in Greater China, expanding development resources and market access while enabling coordinated global development efforts.
Bears Say
Clinical UncertaintyPrograms are early-stage, so clinical proof of benefit is required before therapeutic and commercial potential can be confirmed, leaving valuation contingent on future trial outcomes.
Development Format RiskThe discontinuation of a comparable PD-L1 x VEGF program elsewhere underscores that alternative molecular designs can carry higher development risk and complicate advancement prospects.
Financial RiskA large net loss driven by research and licensing spending increases cash burn and raises the likelihood of needing additional financing, which could dilute existing shareholders.
Crescent Biopharma News
CBIO FAQ
What was Crescent Biopharma’s price range in the past 12 months?
Crescent Biopharma lowest stock price was $8.72 and its highest was $28.77 in the past 12 months.
What is Crescent Biopharma’s market cap?
Crescent Biopharma’s market cap is $333.16M.
When is Crescent Biopharma’s upcoming earnings report date?
Crescent Biopharma’s upcoming earnings report date is Apr 30, 2026 which is in 59 days.
How were Crescent Biopharma’s earnings last quarter?
Crescent Biopharma released its earnings results on Feb 26, 2026. The company reported -$4.01 earnings per share for the quarter, missing the consensus estimate of -$2.471 by -$1.539.
Is Crescent Biopharma overvalued?
According to Wall Street analysts Crescent Biopharma’s price is currently Undervalued.
Does Crescent Biopharma pay dividends?
Crescent Biopharma pays a Quarterly dividend of $0.24 which represents an annual dividend yield of N/A. See more information on Crescent Biopharma dividends here
What is Crescent Biopharma’s EPS estimate?
Crescent Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Crescent Biopharma have?
Crescent Biopharma has 27,556,767 shares outstanding.
What happened to Crescent Biopharma’s price movement after its last earnings report?
Crescent Biopharma reported an EPS of -$4.01 in its last earnings report, missing expectations of -$2.471. Following the earnings report the stock price went down -1.161%.
Which hedge fund is a major shareholder of Crescent Biopharma?
Currently, no hedge funds are holding shares in CBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Crescent Biopharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.71 (145.78% Upside)
$29.71 (145.78% Upside)
Hedge Fund Trend
Increased
By 1.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $18.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.4%
Last 30 Days ▲ 17.5%
Last 30 Days ▲ 17.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.89%
12-Months-Change
Fundamentals
Return on Equity
-51.70%
Trailing 12-Months
Asset Growth
544.72%
Trailing 12-Months
Company Description
Crescent Biopharma
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics, including novel combinations. The company is headquartered in Waltham, Massachusetts.
CBIO Stock 12 Month Forecast
Average Price Target
$29.71
▲(145.78% Upside)
Technical Analysis
Compugen
―
Fate Therapeutics
―
Orchestra BioMed Holdings
―
Fractyl Health, Inc.
―
Actuate Therapeutics, Inc.
―